Whitehawk Therapeutics, Inc.WHWKEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Revenue
$6.2M
Gross Profit
$5.4M
Operating Profit
$-15.6M
Net Profit
$-14.6M
Gross Margin
87.4%
Operating Margin
-252.2%
Net Margin
-236.0%
YoY Growth
-0.4%
EPS
$-0.54
Whitehawk Therapeutics, Inc. Q2 FY2024 Financial Summary
Whitehawk Therapeutics, Inc. reported revenue of $6.2M (down 0.4% YoY) for Q2 FY2024, with a net profit of $-14.6M (up 18.9% YoY) (-236.0% margin). Cost of goods sold was $778.0K, operating expenses totaled $21.0M.
Key Financial Metrics
| Total Revenue | $6.2M |
|---|---|
| Net Profit | $-14.6M |
| Gross Margin | 87.4% |
| Operating Margin | -252.2% |
| Report Period | Q2 FY2024 |
Whitehawk Therapeutics, Inc. Annual Revenue by Year
Whitehawk Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $7.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $7.1M |
| 2024 | $26.0M |
| 2023 | $24.4M |
| 2022 | $15.2M |
Whitehawk Therapeutics, Inc. Quarterly Revenue & Net Profit History
Whitehawk Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-23.3M | N/A |
| Q3 FY2025 | $0 | — | $-17.7M | N/A |
| Q2 FY2025 | $0 | — | $-52.6M | N/A |
| Q1 FY2025 | $7.1M | +33.5% | $73.0M | 1021.9% |
| Q4 FY2024 | $7.2M | +14.4% | $-18.3M | -252.4% |
| Q3 FY2024 | $7.2M | +21.0% | $-12.5M | -174.0% |
| Q2 FY2024 | $6.2M | -0.4% | $-14.6M | -236.0% |
| Q1 FY2024 | $5.4M | -8.8% | $-18.3M | -341.7% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4M | $6.2M | $7.2M | $7.2M | $7.1M | $0 | $0 | $0 |
| YoY Growth | -8.8% | -0.4% | 21.0% | 14.4% | 33.5% | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $111.1M | $101.6M | $85.7M | $70.3M | $234.0M | $180.8M | $167.0M | $150.8M |
| Liabilities | $20.6M | $22.8M | $16.8M | $17.8M | $12.3M | $8.8M | $9.8M | $14.5M |
| Equity | $90.5M | $78.8M | $68.9M | $52.5M | $221.7M | $172.1M | $157.2M | $136.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-19.7M | $-9.2M | $-15.7M | $-15.1M | $-11.9M | $-53.0M | $-15.4M | $-17.2M |